MA27524A1 - Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales - Google Patents

Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales

Info

Publication number
MA27524A1
MA27524A1 MA28263A MA28263A MA27524A1 MA 27524 A1 MA27524 A1 MA 27524A1 MA 28263 A MA28263 A MA 28263A MA 28263 A MA28263 A MA 28263A MA 27524 A1 MA27524 A1 MA 27524A1
Authority
MA
Morocco
Prior art keywords
alkyl
treatment
acyl
aryl
viral infections
Prior art date
Application number
MA28263A
Other languages
English (en)
Inventor
Haigh David
David Hartley Charles
David Howes Peter
Lynette Jackson Deborah
Shah Pritom
John Slater Martin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27524A1 publication Critical patent/MA27524A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Agents antiviraux correspondant à la formule (I) dans laquelle: A représente hydroxy;D représente aryle ou hétéroaryle; Ereprésente hydrogène, alkyle C1-6, aryle, hétéroaryle ou hétérocyclyle; G représente hydrogène ou alkyle C1-6 éventuellement substitué; J représente alkyle C1-6, hétérocyclylalkyle, arylalkyle ou hétéroarylalkyle; et leurs sels, solvates et esters; A est estérifié pour former -OR, et si R est sélectionné entre alkyle, aralkyle, aryloxyalkyle ou aryle à chaîne droite ou ramifiée, R est autre que tert-butyle. L'invention concerne aussi des processus de fabrication, des compositions pharmaceutiques les comprenant et des procédés pour les utiliser dans le traitement de HCV.
MA28263A 2002-10-24 2005-05-06 Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales MA27524A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds

Publications (1)

Publication Number Publication Date
MA27524A1 true MA27524A1 (fr) 2005-09-01

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28263A MA27524A1 (fr) 2002-10-24 2005-05-06 Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales

Country Status (18)

Country Link
US (1) US7304087B2 (fr)
EP (1) EP1554274B1 (fr)
JP (1) JP2006506455A (fr)
KR (1) KR20050057670A (fr)
AR (1) AR041816A1 (fr)
AT (1) ATE418554T1 (fr)
AU (1) AU2003276172A1 (fr)
BR (1) BR0315417A (fr)
CA (1) CA2503471A1 (fr)
CO (1) CO5550450A2 (fr)
DE (1) DE60325498D1 (fr)
IS (1) IS7851A (fr)
MA (1) MA27524A1 (fr)
MX (1) MXPA05004435A (fr)
NO (1) NO20052472L (fr)
PL (1) PL376454A1 (fr)
TW (1) TW200418848A (fr)
WO (1) WO2004037818A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
WO2006050035A1 (fr) 2004-10-29 2006-05-11 Schering Corporation 5-oxo pyrazoles substitues et [1,2,4]triazoles utiles comme agents antiviraux
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
ATE548044T1 (de) 2007-05-04 2012-03-15 Vertex Pharma Kombinationstherapie zur behandlung von hiv- infektionen
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
CA2722102C (fr) 2008-04-28 2013-06-11 Asahi Kasei Pharma Corporation Derive d'acide phenylpropionique et son utilisation
EP2324025A1 (fr) 2008-08-11 2011-05-25 Smithkline Beecham Corporation Dérivés purines destinés à être utilisés dans le traitement de maladies allergiques, inflammatoires et infectieuses
SG193149A1 (en) 2008-08-11 2013-09-30 Glaxosmithkline Llc Novel adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8703754B2 (en) 2010-02-10 2014-04-22 Glaxosmithkline Llc 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
CA2938476A1 (fr) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Derives de pyrrolo[3,2-d]pyrimidine comme inducteurs d'interferon humain
CA2967248A1 (fr) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Derives d'adenine utiles pour traiter des maladies allergiques ou d'autres pathologies inflammatoires
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
KR102527784B1 (ko) 2016-04-07 2023-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조정제로서 유용한 헤테로시클릭 아미드
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
EP3692033A1 (fr) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821670A1 (fr) 1995-04-21 1998-02-04 Novartis AG Amides de n-aroylaminoacide utilises en tant qu'inhibiteurs d'endotheline
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
AU752829B2 (en) 1998-01-26 2002-10-03 Brigham And Women's Hospital Fluorescence imaging endoscope
SK15092000A3 (sk) * 1998-04-23 2001-05-10 Abbott Laboratories Pyrolidíny ako inhibítory neuraminidáz
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (fr) * 2000-01-21 2004-11-24 Alois Ing. Sampl Système d'étagères avec des éléments qui s'insèrent
AU2001259511A1 (en) 2000-05-05 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
EP1339708A2 (fr) 2000-11-20 2003-09-03 Scios Inc. Inhibiteurs de type indole de kinase p38
MXPA04003986A (es) 2001-10-26 2004-07-23 Upjohn Co Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr.
US20050009873A1 (en) 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
WO2004037618A1 (fr) 2002-10-28 2004-05-06 Marquage Antivol Sherlock, Inc. Procédé pour prévenir le vol de véhicules par un marquage intensif

Also Published As

Publication number Publication date
EP1554274A1 (fr) 2005-07-20
US7304087B2 (en) 2007-12-04
BR0315417A (pt) 2005-08-16
PL376454A1 (en) 2005-12-27
MXPA05004435A (es) 2005-07-26
WO2004037818A1 (fr) 2004-05-06
AR041816A1 (es) 2005-06-01
KR20050057670A (ko) 2005-06-16
DE60325498D1 (de) 2009-02-05
ATE418554T1 (de) 2009-01-15
CO5550450A2 (es) 2005-08-31
CA2503471A1 (fr) 2004-05-06
EP1554274B1 (fr) 2008-12-24
TW200418848A (en) 2004-10-01
US20060258720A1 (en) 2006-11-16
JP2006506455A (ja) 2006-02-23
NO20052472L (no) 2005-05-23
AU2003276172A1 (en) 2004-05-13
IS7851A (is) 2005-05-19

Similar Documents

Publication Publication Date Title
MA27524A1 (fr) Derives de 1-acyl-pyrrolidine destines au traitement d'infections virales
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
NO20021528D0 (no) Kinuklidinforbindelser og medikamenter inneholdende de samme som den aktive bestanddel
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00256A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires, et compositions les contenant
TNSN97023A1 (fr) Derives de triazole utiles en therapeutique, procedes pour leur preparation et compositions les contenant.
TNSN97197A1 (fr) Derives de pyrazole parasiticides, procede pour leur preparation et compositions les contenant.
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
CA2443449A1 (fr) Derives de pyrazole pour le traitement de vih
TNSN07022A1 (fr) Derives de pyridine
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1197210A4 (fr) Agents inhibant les reactions de rejet chronique faisant suite a une greffe d'organe
NO20040881L (no) Orale antidiabetes midler.
MA30014B1 (fr) Derives spirocycliques
TNSN99111A1 (fr) Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE3884555D1 (de) Octahydronaphthalenoxim-derivate fuer cholesterolsynthese-inhibierung, verfahren fuer deren herstellung und diese enthaltende zusammenstellungen.
GB0223232D0 (en) Chemical compounds
MA30904B1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90
KR950018037A (ko) 시알산 유도체
TNSN99146A1 (fr) Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
PL334088A1 (en) Novel derivatives of n-benzenesulphonyl-l-proline, methods of obtaining them and pharmaceutic agents
AU2003263455A1 (en) Pyrazole amides for treating hiv infections
TNSN99104A1 (fr) 3 - cetoderives tricycliques de 6 - 0 - methylerythromycine, procede pour leur preparation et compositions pharmaceutiques les contenant